symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
UNCY,0.807,2.536568,58290,28045025,0,0.4-2.87,-0.023,"Unicycive Therapeutics, Inc.",USD,0001766140,US90466Y1038,90466Y103,NASDAQ Capital Market,NASDAQ,Biotechnology,https://www.unicycive.com,"Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.","Dr. Shalabh K. Gupta M.D., MPA",Healthcare,US,12,650 351 4495,4300 El Camino Real,Los Altos,CA,94022,,0,https://financialmodelingprep.com/image-stock/UNCY.png,2021-07-12,False,False,True,False,False
